|
|
|
| Comparison of the effects of different ways of giving Bicalutamide combined with Goserelin in the treatment of advanced prostate cancer and influence on the expression of serum PSA, VEGF and miR-34a |
| LI Xiunan QIN Jie ZHANG Junpeng MA Chuanyu WANG Xingli WU Dongjun CHEN Xiaochi |
| Department of Urology, the First Affiliated Hospital of Dalian Medical University, Liaoning Province, Dalian 116600, China |
|
|
|
Abstract Objective To analyze the effects of different ways of giving Bicalutamide combined with Goserelin in the treatment of advanced prostate cancer and influence on the expression of serum prostate-specific antigen (PSA), vascular endothelial growth factor (VEGF) and miRNA-34a (miR-34a). Methods From February 2015 to December 2016, 80 patients with advanced prostate cancer in the First Affiliated Hospital of Dalian Medical University were selected as research objects, and divided into study group and control group by random number table, with 40 cases in each group. The study group was treated with oral Bicarbonide and subcutaneous injection of Goserelin, when PSA< 0.2 ng/mL, stop taking these two drugs, and when PSA>4 ng/mL, continue to take these two drugs. The control group was given continuous medication. The serum PSA, VEGF, mir-34a and the incidence of urinary tract obstruction were detected and recorded before and after treatment, and the treatment effect, the incictence of adverse effects, the average treatment cost between two groups were compared. Results The serum PSA, VEGF, mir-34a and urinary obstruction of patients in the two groups after treatment for 3, 6, 9 months and 12 months were all lower than those before treatment, the differences were statistically significant (P < 0.05), and the two groups were compared, the differences were not statistically significant (P > 0.05). After treatment, the overall response rate in the study group was higher than control group, the difference was statistically significant (P < 0.05), the average treatment cost in the study group was lower than control group, the difference was statistically significant (P < 0.05), both groups had different levels of adverse reactions, but they were compared, the difference was not statistically significant (P > 0.05). Conclusion Bicalutamide combined with Goserelin intermittent and continuous administration all can improve the serum PSA, VEGF and miR-34a in patients with advanced prostate cancer, while the effect of intermittent administration is more obvious, and the effect is good.
|
|
|
|
|
|
| Cite this article: |
|
LI Xiunan QIN Jie ZHANG Junpeng MA Chuanyu WANG Xingli WU Dongjun CHEN Xiaochi. Comparison of the effects of different ways of giving Bicalutamide combined with Goserelin in the treatment of advanced prostate cancer and influence on the expression of serum PSA, VEGF and miR-34a[J]. 中国医药导报, 2018, 15(6): 53-57.
|
|
|
|
| URL: |
| http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I6/53 |
[1] 牟红云，张鑫圣.戈舍瑞林联合比卡鲁胺间歇性治疗晚期前列腺癌28例[J].医药导报，2011，30（4）：464-466.
[2] 李霖，韩晨东.戈舍瑞林联合比卡鲁胺间歇治疗对前列腺癌患者血清VEGF和miR-34a的影响[J].现代仪器与医疗，2014（2）：45-47.
[3] 李飞宇，王霄英，肖江喜，等.中国男性前列腺癌MRS体素诊断标准[J].中国医学影像技术，2009，25（5）：833-836.
[4] 孙燕.癌症病人三阶梯止痛疗法的指导原则[J].中国肿瘤，1994（4）：15-17.
[5] 张黎明.戈舍瑞林和比卡鲁胺治疗前列腺癌的护理[J].现代实用医学，2007，19（8）：675-676.
[6] 徐辉，王志勇，常辉，等.性激素、前列腺特异性抗原及其相关对前列腺癌的诊断价值[J].中国医药导报，2017，14（15）：76-79.
[7] 马敏，吴海啸，吴汉，等.戈舍瑞林联合比卡鲁胺治疗转移性前列腺癌术后患者的临床效果[J].中国医药，2017， 12（3）：403-406.
[8] Qian SB，Shen HB，Cao QF，et al. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer [J]. Int Urol Nephrol，2015，47（3）：479-484.
[9] 于洪波，于昌连.比卡鲁胺联合戈舍瑞林的不同方法治疗中晚期前列腺癌78例体会[J].世界临床医学，2015（10）：18.
[10] 薛玲，马爱萍.戈舍瑞林联合比卡鲁胺治疗前列腺癌的不良反应及治疗[J].中国保健营养，2013（3）：423.
[11] 何青峰，吴娟，张景宇，等.晚期前列腺癌患者间歇性内分泌治疗的疗效观察[J].中国癌症杂志，2015，12（10）：989-993.
[12] Li YF，Zhang SF，Zhang TT，et al. Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer：a single-arm prospective study using a historical control for comparison [J]. Asian J Androl，2013，15（6）：773.
[13] 翟忠奇，罗晓辉，汤正岐，等.晚期前列腺癌间歇与持续性内分泌治疗的临床观察[J].现代肿瘤医学，2015，23（4）：522-524.
[14] 陈志雄，李黎明，刘晓龙，等.晚期前列腺癌间歇性和持续性内分泌治疗的效果比较及生活质量分析[J].山东医药，2015，25（12）：75-77.
[15] 钱苏波，沈海波，齐隽.比卡鲁胺在去势抵抗性前列腺癌治疗中的应用[J].现代泌尿外科杂志，2014（11）：766-768.
[16] 李明林.比卡鲁胺联合戈舍瑞林间断性治疗前列腺癌临床研究[J].现代肿瘤医学，2015，23（14）：2024-2026.
[17] 曲静坤.比卡鲁胺联合戈舍瑞林间歇性治疗局部晚期前列腺癌的临床评价[J].中国药业，2016，25（11）：46-48.
[18] 张小荣，陈炳.比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌疗效观察[J]. 海峡药学，2012，24（5）：101-103.
[19] 庞宽，周泽光，黄英凡，等.比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌的临床疗效及安全性评价[J].中国临床药理学杂志，2016，3（1）：224-226.
[20] 杨韬.戈舍瑞林与比卡鲁胺联合治疗晚期前列腺癌的疗效分析[J].中国处方药，2016，14（5）：80-81.
[21] 朱煜，张建平，许乐，等.比卡鲁胺治疗中晚期前列腺癌的疗效及安全性分析[J].中国医院用药评价与分析，2010， 10（3）：259-260. |
|
|
|
